AU2005272916A1 - Heterocyclic compounds as pharmaceutical agents - Google Patents

Heterocyclic compounds as pharmaceutical agents Download PDF

Info

Publication number
AU2005272916A1
AU2005272916A1 AU2005272916A AU2005272916A AU2005272916A1 AU 2005272916 A1 AU2005272916 A1 AU 2005272916A1 AU 2005272916 A AU2005272916 A AU 2005272916A AU 2005272916 A AU2005272916 A AU 2005272916A AU 2005272916 A1 AU2005272916 A1 AU 2005272916A1
Authority
AU
Australia
Prior art keywords
optionally substituted
substituted
heteroaryl
heterocyclyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005272916A
Other languages
English (en)
Inventor
Brenton Todd Flatt
Jeffrey Dean Kahl
Richard Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2005272916A1 publication Critical patent/AU2005272916A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2005272916A 2004-08-10 2005-08-09 Heterocyclic compounds as pharmaceutical agents Abandoned AU2005272916A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60023904P 2004-08-10 2004-08-10
US60/600,239 2004-08-10
PCT/US2005/028357 WO2006020680A2 (en) 2004-08-10 2005-08-09 Heterocyclic compounds as pharmaceutical agents

Publications (1)

Publication Number Publication Date
AU2005272916A1 true AU2005272916A1 (en) 2006-02-23

Family

ID=35908114

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005272916A Abandoned AU2005272916A1 (en) 2004-08-10 2005-08-09 Heterocyclic compounds as pharmaceutical agents

Country Status (9)

Country Link
US (1) US7902237B2 (https=)
EP (1) EP1776112A4 (https=)
JP (1) JP2008509912A (https=)
CN (1) CN101010078A (https=)
AU (1) AU2005272916A1 (https=)
BR (1) BRPI0514269A (https=)
CA (1) CA2574279A1 (https=)
MX (1) MX2007001539A (https=)
WO (1) WO2006020680A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090156644A1 (en) * 2005-07-21 2009-06-18 Jacob Westman Use of thiazole derivatives and analogues in the treatment of cancer
DE102007003524A1 (de) * 2007-01-19 2008-09-04 MEDICE Arzneimittel Pütter GmbH & Co. KG Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose
WO2008090356A1 (en) * 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
CN101274918A (zh) * 2007-03-30 2008-10-01 中国科学院上海药物研究所 一类取代五元杂环化合物,其制备方法和医学用途
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
WO2012106581A1 (en) * 2011-02-03 2012-08-09 The University Of Chicago Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction
NZ734451A (en) * 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
JP6556129B2 (ja) 2013-08-01 2019-08-07 アメリカ合衆国 ファルネソイドｘ受容体の阻害剤及び医薬としての使用
SI3043865T1 (sl) 2013-09-11 2021-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
EP2952188A1 (en) * 2014-06-03 2015-12-09 Universität Bern Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
EP3148541B1 (en) 2014-05-28 2020-09-02 Universität Bern Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
EP3715348A1 (en) 2015-03-26 2020-09-30 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
TW201741307A (zh) * 2016-02-22 2017-12-01 艾洛斯生物製藥公司 Ｆｘｒ調節劑及其使用方法
WO2018178260A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
JP2020530477A (ja) * 2017-08-10 2020-10-22 ザ テキサス エーアンドエム ユニヴァーシティ システム Ｎｒ４ａ１リガンド、医薬組成物、及び関連する使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE523919A (https=) * 1952-10-31
US2719162A (en) * 1954-03-29 1955-09-27 Eastman Kodak Co 5-(3-hydroxybenzylidene)-3-phenyl-2-phenylimino-4-thiazolidone and process
US3097100A (en) * 1960-01-25 1963-07-09 Eastman Kodak Co Thiazolidones as light stabilizers for plastic compositions
BE608790A (fr) 1960-10-08 1962-04-03 Kalle Ag Matériel photosensible.
US3314794A (en) 1964-05-13 1967-04-18 Eastman Kodak Co Ultraviolet absorbers
FR1604530A (https=) * 1967-06-06 1971-11-29
US5198454A (en) * 1991-12-03 1993-03-30 Texas A&M University System Use of OB-104 to treat ocular inflammation
JPH06128234A (ja) 1992-10-19 1994-05-10 Fuji Photo Film Co Ltd 不斉炭素原子を有する化合物およびそれからなる非線形光学材料
JP3871354B2 (ja) * 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
US6353006B1 (en) * 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
ES2367539T3 (es) * 2001-12-21 2011-11-04 X-Ceptor Therapeutics, Inc. Moduladores heterocíclicos de receptores nucleares.

Also Published As

Publication number Publication date
EP1776112A4 (en) 2009-11-25
WO2006020680A2 (en) 2006-02-23
BRPI0514269A (pt) 2008-06-10
US7902237B2 (en) 2011-03-08
US20080132519A1 (en) 2008-06-05
EP1776112A2 (en) 2007-04-25
CA2574279A1 (en) 2006-02-23
MX2007001539A (es) 2007-04-23
CN101010078A (zh) 2007-08-01
JP2008509912A (ja) 2008-04-03
WO2006020680A3 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
US8466143B2 (en) Azepine derivatives as pharmaceutical agents
US6696473B2 (en) Heterocyclic modulators of nuclear receptors
EP1521746B1 (en) Quinazolinone modulators of nuclear receptors
JP5420908B2 (ja) 医薬的薬剤としてのアゼピノインドール誘導体
US7902237B2 (en) Heterocyclic compounds as pharmaceutical agents
Alneyadi Rhodanine as a scaffold: a short review on its synthesis and anti-diabetic activities
RU2355686C2 (ru) Ингибиторы глутаминфруктозо-6-фосфатамидотрансферазы
MXPA06000875A (en) Azepine derivatives as pharmaceutical agents
AU2014297912A1 (en) Novel indazole compounds and a process for the preparation thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted